Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) wholly owned subsidiary is the first to pass the consistency evaluation of phloroglucinol injection

Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) announced that Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, received the notice of approval for supplementary application for phloroglucinol injection from the State Drug Administration on March 1, 2022. After review, the drug passed the consistency evaluation of quality and efficacy of generic drugs. Phloroglucinol injection is mainly applicable to acute spastic pain caused by digestive system and biliary tract dysfunction, acute spastic urethral, bladder and renal colic, and gynecological spastic pain. Intercompany pyrogallol injection is the first in China to pass the conformity evaluation of generic drugs.